Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

BACKGROUND: Advanced melanoma is characterized by a pronounced resistance to therapy leading to a limited patient survival of ~6 - 9 months. Here, we report on a novel bifunctional therapeutic fusion protein, designated anti-MCSP:TRAIL, that is comprised of a melanoma-associated chondroitin sulfate...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bruyn, Marco, Rybczynska, Anna A, Wei, Yunwei, Schwenkert, Michael, Fey, Georg H, Dierckx, Rudi AJO, van Waarde, Aren, Helfrich, Wijnand, Bremer, Edwin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000402/
https://www.ncbi.nlm.nih.gov/pubmed/21092273
http://dx.doi.org/10.1186/1476-4598-9-301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000402/
https://www.ncbi.nlm.nih.gov/pubmed/21092273
http://dx.doi.org/10.1186/1476-4598-9-301

Ejemplares similares